Sheridan, M.B.; Bytyci, A.; Stinnett, V.; Umeh, C.; Mari, Z.; Dawson, T.M.; Bodurtha, J.; and Batista, D.A.S.: Myoclonus-dystonia and Silver-Russell syndrome resulting from maternal uniparental disomy of chromosome 7. Clin Genet, doi: 10.1111/cge.12075. [Epub ahead of print], PMID: 23237735, 2012
Umeh, C.C.; Nichols, P.; Rosenthal, L.S. and Mari, Z.: Dual treatment of hemichorea-hemiballismus syndrome with tetrabenazine and chemodenervation. Tremor Other Hyperkinet Mov (N Y), 2. doi:pii: tre-02-113-791-3, Epub 2012
Mari, Z.; Rosenthal, L.S.; Darwin, K.; Hallett, M. and Jinnah, H.A.: Clinical Reasoning: A 57 Year Old Man with Jaw Spasms. Neurology, 80(10):e104-7. doi: 10.1212/WNL.0b013e318285c14a, 2013
Probasco, J.C.; Sahin, B.; Tran, T.; Chung, T.H.; Rosenthal, L.S.; Mari, Z. and Levy, M.: Perioperative Neurological Consultation, The Neurohospitalist, DOI: 10.1177/1941874413476042, 2013
Zakaria, R.; Lenz, F.A.; Hua, S.; Avin, B.H.; Liu, C.C. and Mari, Z.: Thalamic physiology of intentional essential tremor is more like cerebellar tremor than postural essential tremor. Brain Res, doi:pii: S0006-8993(13)00976-1. 10.1016/j.brainres.2013.07.011. [Epub ahead of print], PMID: 23856324, 2013
Ramirez-Castaneda, J.; Jankovic, J.; Comella, C.; Dashtipour, K.; Fernandez, H.H. and Mari, Z.: Diffusion, Spread, and Migration of Botulinum Toxin. Mov Disord. doi: 10.1002/mds.25582. [Epub ahead of print] PMID: 23868503, 2013
Dr. Mari is a team member of the Johns Hopkins Morris K. Udall Parkinson's Disease Research Center of Excellence where he reviews all charts and sees all patients enrolled in the Longitudinal Study at the Udall Center. He is the senior author of a research effort titled “Factors Associated with Falls in Parkinson's Disease”, a project that made use of the Longitudinal Dataset acquired as part of the main clinical research activities at Udall Center and was recently accepted as an abstract publication to the 15th International Congress of Parkinson’s Disease and Movement Disorders.
Dr Mari's research focuses on clinical trials in Parkinson’s disease modification and neuroprotection, and the neurophysiology of and motor control in movement disorders, with particular interest in basal ganglia pathophysiology in dystonia. In his leadership of the Deep Brain Stimulation Program at Johns Hopkins Hospital he has been the principal investigator on multiple major NIH-funded clinical trials on neuroprotection in Parkinson disease, including the NET-PD and QEIII trials (to investigate the possible disease modifying effect of creatine and Coenzyme Q10, respectively).
Learn more about active clinical trials taking place at the Johns Hopkins Parkinson’s Disease and Movement Disorders Center.